PhotoMedex Inc.

PhotoMedex Inc. specializes in dermatology technologies, offering innovative solutions for skin rejuvenation and disease management. They focus on advanced laser systems and fiber-optic treatments to enhance patient care and outcomes. Founded in 1987 in Montgomeryville, US, PhotoMedex Inc.

is dedicated to developing advanced dermatological solutions. The company underwent a significant merger with Radiancy Inc. in July 2011, enhancing its product portfolio. Matthew Call is the current CEO.

The company has raised a total of USD 22. 40 mn across various funding rounds, including a RECAPITALISATION round of USD 22. 40 mn, which contributed to its financial stability and growth. PhotoMedex is a prominent player in the dermatology sector, specializing in disease management and skin rejuvenation through an extensive range of innovative products and services.

Central to its offerings is the XTRAC excimer laser system, the first FDA market-cleared device for treating dermatological conditions such as psoriasis and vitiligo. This system employs high doses of UVB energy, targeting affected areas while minimizing exposure to surrounding healthy skin. The company also provides fiber-optic systems designed for treating cardiovascular and vascular diseases, demonstrating its versatility in medical applications beyond dermatology. PhotoMedex serves a diverse clientele, including dermatologists and medical professionals in North America, Europe, and parts of Asia, who utilize these technologies to address various skin conditions and enhance aesthetic outcomes.

In the most recent year of 2018, PhotoMedex reported a revenue of USD 41,000, with an EBITDA of -USD 5,638,000. The company generates revenue primarily through the sale of its flagship products, including the XTRAC excimer laser system and accompanying therapeutic solutions. The transaction structure typically involves direct sales to healthcare providers, dermatology clinics, and healthcare institutions, where these products are integrated into their treatment protocols. Additionally, the company may engage in partnerships with distributors and wholesalers to expand its market reach.

Revenue is derived from one-time sales of equipment, as well as recurring sales of consumables and maintenance services associated with the laser systems, contributing to the company's overall financial health. PhotoMedex aims to leverage its recent funding of USD 22. 40 mn to further develop and market new products, particularly in advanced laser technologies for dermatological treatment. The company is also focusing on expanding its presence in Europe and Asia by the end of 2022, targeting specific markets to enhance its distribution network.

Furthermore, the strategic use of funds from past investment rounds will support these initiatives, particularly in marketing and product development, as well as operational enhancements.